Abstract
Human E1 is a key player in protein ubiquitination, however the E1 structure is not available. In this paper, we describe the derivation of a human E1 structure using molecular modelling based on the crystal structure of S. cerevisiae E1 and M. Musculus E1. Key interactions between our E1 model and ubiquitin are also discussed.
Keywords: Ubiquitination, Human E1, Ubiquitin activating enzyme, Homology modelling
Letters in Drug Design & Discovery
Title: Homology Modelling of Human E1 Ubiquitin Activating Enzyme
Volume: 7 Issue: 1
Author(s): Ghali Brahemi, Angelika M. Burger, Andrew D. Westwell and Andrea Brancale
Affiliation:
Keywords: Ubiquitination, Human E1, Ubiquitin activating enzyme, Homology modelling
Abstract: Human E1 is a key player in protein ubiquitination, however the E1 structure is not available. In this paper, we describe the derivation of a human E1 structure using molecular modelling based on the crystal structure of S. cerevisiae E1 and M. Musculus E1. Key interactions between our E1 model and ubiquitin are also discussed.
Export Options
About this article
Cite this article as:
Brahemi Ghali, Burger M. Angelika, Westwell D. Andrew and Brancale Andrea, Homology Modelling of Human E1 Ubiquitin Activating Enzyme, Letters in Drug Design & Discovery 2010; 7 (1) . https://dx.doi.org/10.2174/157018010789869316
DOI https://dx.doi.org/10.2174/157018010789869316 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Enzyme Inhibition Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer
Current Cancer Drug Targets Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides
Current HIV Research Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Putative Mechanisms of Viral Transmission and Molecular Dysregulation of Mammary Epithelial Cells by Human Papillomavirus: Implications for Breast Cancer
Current Molecular Medicine The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Analysis of Codon Usage Patterns in the Human Papillomavirus Oncogenes
Current Bioinformatics Natural Product Gossypol and its Derivatives in Precision Cancer Medicine
Current Medicinal Chemistry CD93: Recent Advances and Implications in Disease
Current Drug Targets Hedgehog Signaling in the Normal and Neoplastic Mammary Gland
Current Drug Targets Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Developing Immunologically Inert Adeno-Associated Virus (AAV) Vectors for Gene Therapy: Possibilities and Limitations
Current Pharmaceutical Biotechnology Cathepsin L Induces Proangiogenic Changes in Human Omental Microvascular Endothelial Cells via Activation of the ERK1/2 Pathway
Current Cancer Drug Targets Polymeric Drug Delivery Approaches for Colon Targeting: A Review
Drug Delivery Letters Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry